Nokia has announced plans to acquire Withings S.A., a pioneer and leader in the connected health revolution with a family of award-winning digital health products and services to help people all over the world lead healthier, happier and more productive lives. Withings will be part of our Nokia Technologies business.
“We have said consistently that digital health was an area of strategic interest to Nokia, and we are now taking concrete action to tap the opportunity in this large and important market,” said Rajeev Suri, president & CEO of Nokia. “With this acquisition, Nokia is strengthening its position in the Internet of Things in a way that leverages the power of our trusted brand, fits with our company purpose of expanding the human possibilities of the connected world, and puts us at the heart of a very large addressable market where we can make a meaningful difference in peoples’ lives.”
“Withings shares our vision for the future of digital health and their products are smart, well designed and already helping people live healthier lives,” said Ramzi Haidamus, president of Nokia Technologies. “Combining their award-winning products and talented people with the world-class expertise and innovation of Nokia Technologies uniquely positions us to lead the next wave of innovation in digital health.”
The combination of innovative products from Withings and the Digital Health business will also ensure the ongoing renewal of Nokia Technologies’ world class IPR portfolio.
The planned transaction values Withings at EUR 170 million and would be settled in cash and is expected to close in early Q3, 2016 subject to regulatory approvals and customary closing conditions.
Richard Wolf launched a new “ENDOCAM Flex HD” video solution to the market.
The ENDOCAM Flex HD has already been presented to a broadly based professional public at the MEDICA International Trade Fair for Medical Technology in 2015. The compact construction and the universal options for application mean that users can carry out endoscopic treatments flexibly, quickly and simply with the ENDOCAM Flex HD.
A combination of appealing value for money and a customer-centric service concept also provide attractive reasons to invest in this camera system.
The medical technology manufacturer has collected feedback and opinions at http://endocamflexhd.richard-wolf.com/en.html and summarized them on a OnePage layout. Images and clips complement advantages of the new video solution there. Richard Wolf also provides the option of ordering a Test Set so that users in private practices and in hospitals have an opportunity to find out about the impressive features of the ENDOCAM Flex HD.
AtriCure, Inc. announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the AtriClip PRO2 Left Atrial Appendage (LAA) Exclusion System. The new AtriClip PRO2 system has increased functionality which enhances the capability to occlude the LAA during minimally-invasive surgical (MIS) procedures.
The AtriClip PRO2 system features an ambidextrous locking and trigger-style clip closing mechanism, handle-based active articulation levers, and a hoopless end effector. The ambidextrous locking and trigger-style clip closing mechanism allows the operator to maintain focus on the LAA while maneuvering the device. The handle-based active articulation levers allow the operator to steer the end effector without removing the device. The hoopless end effector enhances anatomical visualization, and simplifies removal of the applier after deployment of the clip.
AtriCure was the first company to receive FDA clearance for a device designed specifically for occluding the LAA. Through the previous twelve months ending December 31, 2015, sales of AtriClip products grew at a rate of 45% on a global basis as compared to the prior period in 2014. To date, AtriClip products have been used to treat more than 70,000 patients worldwide.
The 3M Intelligent Control Inhaler provides a number of unique features that offer opportunities to improve outcomes by reducing patient variability and errors, and providing data on use to health care providers and payers:
- Controlled inspiration: a combination of breath actuation with innovative technology to control inspiratory flow rate significantly reduces errors in technique, and results in a much higher level of consistency of drug delivery between breaths and between patients.
- Integrated patient instructions: the inhaler’s patient-proof design gives patients confidence to use the inhaler correctly and helps eliminate critical errors in use, as well as minimizing the resources dedicated to training patients in correct inhalation technique.
- Fully integrated device: the dose is registered when the patient correctly inhales medication rather than on actuation of the device, delivering greater accuracy of information for the patient, and cost-savings for health care providers who can avoid unnecessary switches and treatment escalation.
- Capture of inspiration data: the inhaler utilizes a data management platform to record not only device usage, but also inspiration profiles to help monitor disease progression, further supporting informed treatment decisions.
The device will be developed in partnership with a pharmaceutical company, and is expected to be in wide use by the end of the decade.
For more information please visit 3M website by clicking here.
BD (Becton, Dickinson and Company) announced a new line of surgical instrument sterilization containers that are validated for the latest low-temperature sterilization processes.
The Genesis™ Low Temperature Rigid Sterilization Container System is validated for newer low-temperature sterilization processes and systems from market-leading sterilizer manufacturers, including the V-PRO® Low Temperature Sterilization Systems from STERIS and STERRAD® Systems from Advanced Sterilization Products (ASP). Low-temperature sterilization is a fast-growing trend in sterile processing and is used for instrumentation that cannot withstand the high-temperature and moisture present in traditional steam sterilization practices.
The new containers have a visually differentiated set of orange components to quickly and easily differentiate them from Genesis containers indented for other sterilization processes. The line provides long-lasting protection and sterility maintenance for surgical instrumentation. Genesis containers are offered in a variety of sizes to help organize and secure instruments prior to surgery. Genesis containers also provide an environmentally friendly alternative to sterilization wrap.
AtriCure, Inc received 510(k) clearance for the cryoFORM cryoablation probe, which offers increased probe flexibility to adapt to a variety of surgical ablation procedures. The probe was previously launched in October 2015 in the European market under a CE mark.
“We are excited to bring this new technology to the U.S. market,” said Mike Carrel, President and CEO of AtriCure. “Since the launch in Europe, we have received very positive feedback from our customers, and are looking forward to continued growth in our cryoablation platform.”
The cryoFORM probe builds off of the company’s core strengths in cryoablation technology, leveraging such important features as thermal capacity to remove heat and active defrost, which offers the increased probe flexibility necessary for minimally invasive cardiac surgeries. Building upon those strengths, the new probe offers increased flexibility, allowing the surgeon to more easily manipulate and apply the device and conform to challenging anatomies.
“The flexibility of cryoFORM, together with the automatic defrost function of the CryoICE system, made us decide at the Heart Center Leipzig to start using this product for our cryoablation procedures,” said Dr. Martin Misfield, MD, PhD, Professor and Co-Director, Department of Cardiac Surgery, Heart Center, University of Leipzig.